Target Name: CDC42SE1
NCBI ID: G56882
Review Report on CDC42SE1 Target / Biomarker Content of Review Report on CDC42SE1 Target / Biomarker
CDC42SE1
Other Name(s): CDC42 small effector 1 | CDC42SE1 variant 1 | SCIP1 | C42S1_HUMAN | Signaling molecule SPEC1 beta | Small effector of CDC42 protein 1 | 1300002M12Rik | CDC42 small effector protein 1 | small protein effector 1 of Cdc42 | Small protein effector 1 of Cdc42 | small effector of CDC42 protein 1 | CDC42-binding protein SCIP1 | CDC42 small effector 1, transcript variant 1 | SPEC1 | signaling molecule SPEC1 beta

CD42SE1: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the production of immune cells in the central nervous system that attack the myelin sheath. The immune response against the myelin sheath leads to the damage of nerve fibers, leading to symptoms such as muscle weakness, vision problems, and balance issues. There is currently no cure for MS, and existing treatments are only designed to manage symptoms. Therefore, the discovery of new drug targets and biomarkers for MS is crucial for the development of new treatments.

CDC42SE1: A Potential Drug Target

The protein CD42SE1, also known as CDC42 small effector 1, has been identified as a potential drug target for MS. CD42SE1 is a protein that is expressed in many different tissues in the body, including the brain, spinal cord, and peripheral nerves. It is involved in the immune response and has been implicated in the development of MS.

Studies have shown that CD42SE1 is involved in the immune response against the myelin sheath. It has been shown to interact with immune cells that are involved in the development of MS, including T-cells and macrophages. Additionally, studies have shown that CD42SE1 is involved in the regulation of the immune response and has been implicated in the immune tolerance system.

Furthermore,CD42SE1 has been shown to play a role in the regulation of pain perception. It has been shown to interact with pain receptors and contribute to pain perception. Therefore, it is possible that CD42SE1 could be a potential drug target for MS.

CD42SE1 as a Biomarker

CD42SE1 has also been shown to be a potential biomarker for MS. The development of MS is associated with changes in the immune system, including an increase in the number of immune cells in the central nervous system. Therefore, measuring changes in the levels of CD42SE1 in the immune cells, as well as changes in the immune system in general, could be a useful diagnostic tool for MS.

CD42SE1 has been shown to be involved in the regulation of immune cell function, including the regulation of T-cells. T-cells are a type of immune cell that play a crucial role in the immune response against MS. Therefore, changes in the levels of CD42SE1 in T-cells could be an important biomarker for MS.

CD42SE1 has also been shown to be involved in the regulation of immune cell function, including the regulation of macrophages. Macrophages are another type of immune cell that play a crucial role in the immune response against MS. Therefore, changes in the levels of CD42SE1 in macrophages could also be an important biomarker for MS.

Conclusion

CDC42SE1 is a protein that has been shown to be involved in the immune response and has been implicated in the development of MS. Studies have shown that CD42SE1 interacts with immune cells that are involved in the development of MS and that it plays a role in the regulation of the immune response. Furthermore, studies have shown that CD42SE1 is involved in the regulation of pain perception and has been shown to interact with pain receptors. Therefore, CD42SE1 is a potential drug target and biomarker for MS. Further studies are needed to confirm its potential as a drug target and biomarker for MS.

Protein Name: CDC42 Small Effector 1

Functions: Probably involved in the organization of the actin cytoskeleton by acting downstream of CDC42, inducing actin filament assembly. Alters CDC42-induced cell shape changes. In activated T-cells, may play a role in CDC42-mediated F-actin accumulation at the immunological synapse. May play a role in early contractile events in phagocytosis in macrophages

The "CDC42SE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC42SE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D